Metabolic disorders

Metabolic diseases, which are primarily associated with disturbances in normal energy metabolism, and are tremendously affected by the composition of the gut microbiota, are among the leading causes of morbidity and mortality in individuals after age 60. There are numerous types of inherited or acquired metabolic disorders, leading to a variety of diseases ranging from the rare “orphan” disorders to those that affect millions people worldwide such as diabetes and obesity.

Recently, Human Microbiology Institute researchers have made amazing advances in understanding the mechanisms that govern metabolic-related processes at the level of host-microbiota interference. Indeed, HMI scientists are currently intensively studying the underlying roles of the microbiota in type 2 diabetes, obesity, gout, etc. This research will provide insights that may facilitate the development of new therapeutic strategies and compounds for these metabolism-related disorders.


Novel Pathogens Search

The HMI is working to elucidate the particularities of host-microbiota cross-talk, and identify infectious agents that might trigger the onset and progression of metabolic disorders.

Using unique methods developed by HMI founders they , we have already identified several novel pathogens and have evaluated their effects on human-microbiota cross-talk. These studies will further our understanding of the pathogenesis of metabolic disorders and will thereby facilitate the development of methods for preventing and treating these diseases, and may ultimately give rise to a system for personalized microbiota care.

Novel Therapeutic Directions


The HMI is currently developing a unique product that is based on unanticipated results obtained from a study of distinct mechanisms of cooperation between the microbiota and mitochondria, named “HMI-M-Transplantat”. This therapeutic solution for the first time takes into consideration the unexpected link between the microbiota and the host organism, and is based on the Tetz’s Theory of longevity, maternal inheritance of microbiota, diseases of the microbiota, and the Pangenome concept. Moreover, the HMI is developing individualized algorithms for the usage of this unique product to prevent and overcome metabolic disorders.


HMI scientists are currently developing a new compound that exhibits multipotent targeting. Using this compound, it may be possible to effectively treat and prevent metabolic disorders.


Our research, based on theories developed here at the HMI, has revealed entirely new aspects of the biology of metabolic disorders, and has identified a new group of potential therapeutic targets. By targeting these factors, it may be possible to control the progression of metabolic disorders. Moreover, our findings have resulted in the development of a first-in-class, potentially groundbreaking, therapeutic solution named NT-49, which is currently under intensive study at the HMI.

The Human Microbiology Institute is dedicated to collaborate with other research organizations and entities involved in this field. To that end the HMI will develop means by which to make the results of this research widely available on a non- discriminatory basis.